Key Highlights

● Revenue and gross Margin rose

● Small operating profit led by Greenbrook clinics

● Quarterly report cites substantial doubt about going concern

● Projected covenant shortfall next March

Neuronetics, Inc. (NASDAQ:STIM), one of the penny stocks in healthcare combining a medical device Business with a psychiatric clinic network, said that it Earned income from operations in the third quarter, compared with a sizable operating loss a year earlier. Revenue climbed from the prior-year period, gross margin widened, and the Malvern, Pennsylvania company lowered its full-year Operating Expense guidance while keeping its revenue range unchanged.

A different note appeared in the quarterly filing the company made with the Securities and Exchange Commission. There, management projected that trailing annual revenue for the period ending in March next year would fall below the minimum set in its Credit agreement, and the filing states that "substantial doubt exists about the Company's ability to continue as a going concern." The company was in compliance at the end of September, and it is in discussions with its lender. Both pictures are accurate at once, which is what makes this quarter unusual.

Device and Clinic Lines Growing at Different Speeds

Neuronetics now reports through a pair of segments. NeuroStar sells transcranial magnetic stimulation systems and treatment sessions to practices, while Greenbrook operates a network of interventional psychiatry clinics offering both TMS and SPRAVATO. The company acquired Greenbrook earlier, and the combination has altered its revenue profile substantially.

Greenbrook supplied nearly all of the third-quarter growth. Its revenue rose at a double-digit rate, and it now accounts for well over half of the total. NeuroStar revenue increased only marginally from the prior-year quarter. Over the year to date, the split was starker: Greenbrook grew, whereas NeuroStar revenue slipped slightly from the same period last year.

Chief Executive Dan Reuvers described the strategy as "taking hold," citing a record third quarter within Greenbrook and in NeuroStar system sales. His predecessor, Keith Sullivan, had planned to retire this year, as Market commentary noted in its coverage of the prior-year quarter.

What Drove the Margin Gain at the Clinics

Gross margin expanded markedly from the prior-year quarter. The company credited a new go-to-market strategy and improved revenue cycle management at the Greenbrook clinics. Revenue cycle management refers to the administrative chain that runs from qualifying a patient through submitting a claim and collecting payment, and in a clinic business reliant on insurers, small improvements there can reach the margin directly.

On the earnings call, as shown in a transcript, management pointed to better qualification, cleaner claims and faster collections. It said an AI-enabled coding tool called Skypoint had lifted first-month collections. It also cautioned that some prior-period catch-ups included in the margin gains were not expected to recur, an important qualification for anyone extrapolating from this quarter. The published transcript is machine-assisted and contains some errors, so company filings are the controlling source for figures.

Spravato also contributed to growth. Management described that treatment as more durable because of its maintenance phase, which can keep patients returning over a longer period. Clinic occupancy remains uneven, ranging from low levels at the weakest clinics to much higher levels at the strongest, and management called closing that gap a priority. That spread suggests available capacity within the existing footprint, without necessarily requiring new sites.

A Deliberate Shift in the Device Business

The NeuroStar segment is in transition by design. Management said on the call that Capital sales grew strongly and that more than half of the units sold were capital or Lease units, which carry higher average selling prices and margins. Treatment session revenue, by contrast, is declining as expected under the new strategy, and management anticipates a further slight downward trend.

That shift changes the character of NeuroStar revenue: more of it arrives upfront in system sales, while less comes through recurring session purchases. The company is also targeting broader customer segments, including national and multisite accounts, and it cited a recently awarded sole-source agreement with a large national player.

Cost Discipline and the Lower Expense Guide

Total operating expenses fell from the prior-year quarter, mainly because of lower sales and Marketing spending, partly offset by higher general and administrative costs. Research and Development also declined slightly. Those reductions, combined with higher gross profit, produced income from operations and positive adjusted EBITDA, against a loss on both measures a year earlier.

The Bottom Line remained in the red. Net loss attributable to stockholders narrowed considerably from the prior-year period, and items below the operating line more than absorbed the operating gain. The weighted share count was also higher than a year earlier, and the filing cites remaining capacity under an at-the-market Equity program.

Management raised the low end of its gross margin guidance and lowered its operating expense range. Operating and investing Cash Flow guidance also improved, with the anticipated full-year outflow narrowing at both ends. Stock-based compensation is now expected to be lower than previously projected. The revenue range did not change. Taken together, the update implies better profitability on the same sales, rather than a stronger top line.

Management also indicated, according to the call transcript, that it is Rebalancing part of its direct-to-consumer Advertising at Greenbrook toward field sales, adding representatives to the existing team with a full ramp expected by the middle of next year. That reallocation is intended to support growth next year, and its effect is not yet measurable.

The Balance Sheet Behind the Income Statement

The balance sheet at the end of September showed cash and restricted cash below the year-end level, and Accounts Receivable modestly lower. Inventory rose slightly. Total Assets declined, with Goodwill unchanged and intangible assets down slightly, while total liabilities also fell. Long-term Debt decreased after the first-quarter repayment, and accrued expenses came down as well.

Stockholders' equity was thin relative to total liabilities and declined during the year as the accumulated Deficit grew. Restructuring expense was a small item in the quarter, and the year-to-date amount remained modest. Stock-based compensation dropped sharply in the third quarter compared with the year-to-date run rate, consistent with the lower full-year figure now in the guidance.

Year-to-date figures put the single quarter in context. Total revenue increased from the same period of last year, Gross Profit rose, and the operating loss was far smaller. Adjusted EBITDA remained negative across that longer period, however, so the third quarter represents an improvement within a year still showing losses, not a full-year reversal.

Reading the Going-Concern Language

Going-concern language appears when management concludes that conditions raise substantial doubt about a company's ability to meet its obligations over the coming year. In this case the filing ties the doubt specifically to a revenue covenant in its credit agreement rather than to an immediate shortage of cash. Quarterly revenue covenants were modified by an amendment in March, through the end of this year, and Liquidity covenants were modified through the following September.

Under the filing, if the minimum revenue covenant is missed at the end of March, the lender may call the Facility at its discretion, and the company does not project having the liquidity to repay it. The outstanding borrowings, which mature later in the decade, are substantially larger than the cash balance. Management cited revenue cycle improvements, new clinic treatment Options and NeuroStar sales strategies as mitigating actions but said these do not fully mitigate the covenant risk.

Cash and cash equivalents fell during the year, and the accumulated deficit increased. The company repaid part of its debt to Perceptive Advisors in the first quarter, recording a small loss on partial extinguishment. Operating and investing cash flow was slightly positive in the third quarter, an improvement over the outflow in the prior-year quarter. That single-quarter improvement is useful evidence, yet it does not change the covenant arithmetic described in the filing.

The call transcript contains no covenant discussion, according to the version reviewed. The primary record of this risk is therefore the Quarterly Report and the forward-looking statement section of the earnings release, which lists the ability to continue as a Going Concern among its risk factors.

Regulatory Filings That Could Widen the Device Label

Neuronetics has several regulatory and product items in progress. In August, it submitted a premarket notification to the Food and Drug Administration for an accelerated TMS protocol, which remains under review. The company said condensed protocols may suit some patients better and could expand access. Standard TMS courses typically require repeated clinic visits, so a shorter schedule addresses a practical barrier, although the outcome of the review is unknown.

The company also signed a distribution agreement with Wave Neuroscience and plans to seek FDA clearance so NeuroStar systems can treat post-traumatic stress disorder using Wave's EEG-based software algorithm. Any launch depends on that clearance. NeuroStar is currently cleared for adults with major depressive disorder, as an adjunct for obsessive-compulsive disorder, for anxious depression, and as a first-line adjunct for major depressive disorder in adolescents and young adults, as market data and the company describe it.

On the call, management also referred to a large patient analysis indicating no significant difference in outcomes for short gaps in treatment. Such data bears on how flexibly clinics can schedule patients, although the transcript offers only limited detail on the study.

The Software Link With AdvancedMD

In September, the company announced the integration of its TrakStar practice management platform with AdvancedMD, a cloud-based electronic health record, practice management and revenue cycle platform. Neuronetics described it as the first TMS integration with an EHR or EMR system. Treatment data flows into the same system used for scheduling, clinical records and billing, which the company said can reduce duplicate work.

AdvancedMD reports serving a very large base of practitioners and independent practices. The third-quarter release says availability for existing AdvancedMD users is expected in the fourth quarter. Stephanie Cho, chief marketing officer of AdvancedMD, said in the September announcement that "Adding TMS is a clinical decision, but sustaining it is an operational one." Neuronetics said it plans further integrations, and that availability, features and timing may change.

Access and Coverage as a Backdrop

Treatment access has been a running theme in the company's disclosures. Market commentary noted last year that New York State Medicaid had expanded coverage for TMS therapy, including NeuroStar, for adults with major depressive disorder, a step covering a very large number of members statewide. Coverage decisions of that kind matter to both segments, because they affect how many patients can reach treatment and how practices are paid.

Market data also describes the Greenbrook centres as operating across the US and offering SPRAVATO nasal spray, which is approved for adults with treatment-resistant depression, alone or alongside an oral antidepressant, and with an oral antidepressant for depressive symptoms in adults with major depressive disorder who have acute suicidal Ideation or behavior. The company's materials carry a footnote stating that the effectiveness of SPRAVATO in preventing suicide or reducing suicidal ideation has not been demonstrated.

Psychedelics Preparation at Greenbrook

Reuvers also mentioned preparation for psychedelic therapies, an area where the clinic network could act as a delivery site. According to the call transcript, management expects Compass Pathways to make an FDA submission soon for its investigational treatment and anticipates a launch in the first half of next year, and Greenbrook is positioning itself as a delivery platform modelled on its SPRAVATO operations, initially using a hub-and-spoke approach.

These expectations are those of Neuronetics management on the call, and they depend on another company's filing and on a regulatory decision that has not been made. The release mentions no associated revenue.

Where the Numbers Point Next

Set against year-to-date revenue, the unchanged range implies a fourth quarter at or above the third-quarter level, and management said on the call that it targets limited to no net cash use in the second half. NeuroStar revenue mix is expected to lean slightly toward capital sales in the fourth quarter, and Greenbrook marketing spend is being rebalanced.

Beyond that lies the date that the filing itself highlights. Trailing revenue at the end of that March test, and the outcome of discussions with the lender, will shape how the going-concern doubt develops. Analysts from Canaccord, B. Riley, BTIG and Citizens JMP asked on the call about Greenbrook capacity, the design of a Compass pilot, the durability of revenue cycle gains and margin drivers, according to the transcript, indicating the operational areas receiving the closest outside attention. No view on valuation or future share performance is offered here, and the company's disclosures make clear that both outcomes remain uncertain.